Protagenic Therapeutics, Inc.·Healthcare

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB® and has commenced trading on OTCQB under the symbol "PTIX." The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification and bid price standards.

Atrinsic Inc. (NASDAQ: PTIX - Get Free Report)'s stock price was up 10.9% during trading on Tuesday. The company traded as high as $0.50 and last traded at $0.50. Approximately 2,974 shares traded hands during trading, a decline of 96% from the average daily volume of 77,387 shares. The stock had previously closed at $0.4507.

Atrinsic (NASDAQ: PTIX - Get Free Report) and Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Analyst Ratings This is a summary of recent
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.